Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has announced the launch of its generic Semaglutide Injection in Canada. This development follows the receipt of the Notice of Compliance (NOC) from Health Canada on April 28, 2026, marking Dr. Reddy’s as the first company to receive such approval for a generic Semaglutide Injection in Canada. Canada is also the first G7 country to grant market authorisation for this product.
The Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with diet and exercise. It is available as a sterile solution for subcutaneous injection in pre-filled pens, with strengths of 2 mg/pen and 4 mg/pen, delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver doses of 0.25 mg or 0.5 mg, while the 4 mg/pen delivers 1 mg doses per injection.
Erez Israeli, Chief Executive Officer of Dr. Reddy’s, expressed satisfaction with the launch, stating, “We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development. With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients.”
The launch in Canada builds on the momentum of Dr. Reddy’s recent introduction of the product in India under the brand name Obeda®. The company is actively working to expand access to GLP-1 therapies across multiple global markets.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).